A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.

Also called NCT07564414

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,500 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07564414
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, South Africa, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07564414. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-21 (actual); primary completion 2028-02-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Condition
Obesity
Intervention (Drug)
Cagrisema
Intervention (Drug)
Semaglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07564414
Content hash
7d7075abd9009fb3695002cd7be5808cb8a044113247752764edb90cbb23cf4d